Verinurad does not prolong QTc interval: a thorough QT study using concentration

Verinurad does not prolong QTc interval: a thorough QT study using concentration–QTc modelling

Published:2023-01-02 Issue: Volume: Page:
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Brit J Clinical Pharma

Author:

Parkinson Joanna¹^ORCID,Dota Corina²,Källgren Christian³,Gottfridsson Christer²,Bjursell Magnus³,Perl Shira⁴,Kӧrnicke Thomas⁵,Rekić Dinko¹,Johansson Susanne¹^ORCID

Affiliation:

1. Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences R&D AstraZeneca Gothenburg Sweden

2. Cardiovascular Safety Center of Excellence and Safety Knowledge Group, Global Patient Safety, Oncology R&D AstraZeneca Gothenburg Sweden

3. Late‐Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D AstraZeneca Gothenburg Sweden

4. Late‐Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D AstraZeneca Gaithersburg Maryland USA

5. Early Phase Clinical Unit Parexel International Berlin Germany

Funder

AstraZeneca

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.15637

Reference32 articles.

1. Role of uric acid in hypertension, renal disease, and metabolic syndrome.

2. Elevated Uric Acid Increases the Risk for Kidney Disease

3. An evidence-based review on urate-lowering treatments: implications for optimal treatment of chronic hyperuricemia

4. Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation

5. THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Overview

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 9-Hydroxy-8-oxypalmatine, a novel liver-mediated oxymetabolite of palmatine, alleviates hyperuricemia and kidney inflammation in hyperuricemic mice;Journal of Ethnopharmacology;2024-12

2. Overview of the pharmacokinetics and pharmacodynamics of URAT1 inhibitors for the treatment of hyperuricemia and gout;Expert Opinion on Drug Metabolism & Toxicology;2023-11-25